KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue: 2011-2017

Historic Non-Current Deffered Revenue for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Dec 2017 value amounting to $1.1 million.

  • Supernus Pharmaceuticals' Non-Current Deffered Revenue fell 23.45% to $1.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.1 million, marking a year-over-year decrease of 23.45%. This contributed to the annual value of $1.1 million for FY2017, which is 23.45% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non-Current Deffered Revenue of $1.1 million as of Q4 2017, which was down 5.90% from $1.2 million recorded in Q3 2017.
  • Supernus Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $1.7 million during Q1 2016, with a 5-year trough of $738,000 in Q2 2013.
  • Its 3-year average for Non-Current Deffered Revenue is $1.4 million, with a median of $1.3 million in 2017.
  • In the last 5 years, Supernus Pharmaceuticals' Non-Current Deffered Revenue surged by 358.58% in 2013 and then dropped by 23.45% in 2017.
  • Over the past 5 years, Supernus Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $1.4 million in 2013, then dropped by 10.09% to $1.3 million in 2014, then increased by 9.11% to $1.4 million in 2015, then rose by 7.99% to $1.5 million in 2016, then decreased by 23.45% to $1.1 million in 2017.
  • Its Non-Current Deffered Revenue was $1.1 million in Q4 2017, compared to $1.2 million in Q3 2017 and $1.3 million in Q2 2017.